RNS Number : 9260J MaxCyte, Inc. 29 April 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 29 April 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
RNS Number : 5031I MaxCyte, Inc. 19 April 2022 MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , April 19, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform
RNS Number : 1844I MaxCyte, Inc. 13 April 2022 MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue GAITHERSBURG, MD , April 13, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering
RNS Number : 8763H MaxCyte, Inc. 11 April 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 9191G MaxCyte, Inc. 01 April 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 April 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
RNS Number : 2646G MaxCyte, Inc. 28 March 2022 The following amendments have been made to the Grant of Options and PDMR Dealing announcement released on 28 March 2022 at 07:00 under RNS number 1548G. An incorrect Identification Code in section 4.b has been removed.
RNS Number : 1548G MaxCyte, Inc. 28 March 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options and PDMR Dealing Gaithersburg, Maryland - 28 March 2022 : MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling
RNS Number : 6718F MaxCyte, Inc. 23 March 2022 MaxCyte Reports Fourth Quarter and Full Year Financial Results MaxCyte Provides Initial 2022 Guidance GAITHERSBURG, MD , March 23, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused
RNS Number : 2726E MaxCyte, Inc. 10 March 2022 MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer Dr . Sumen brings extensive experience in scientific and technology evaluation, process development and leadership. GAITHERSBURG, Md. Mar. 10, 2022 - MaxCyte, Inc.
RNS Number : 0701E MaxCyte, Inc. 08 March 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
